(S)-2-[(叔丁氧羰基)氨基]-5-(二甲基氨基)戊酸 | 65671-54-7

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (S)-2-[(叔丁氧羰基)氨基]-5-(二甲基氨基)戊酸
• 中文别名: (S)-2-[(叔丁氧基羰基)氨基]-5-(二甲基氨基)戊酸
• 英文名称: (S)-2-tert-butoxycarbonylamino-5-dimethylamino-pentanoic acid
• 英文别名: (S)-2-(tert-butoxycarbonylamino)-5-(dimethylamino)pentanoic acid；2(S)-(+)-tert-butoxycarbonylamino-5-dimethylaminopentanoic acid；(2S)-5-(dimethylazaniumyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoate
• CAS: 65671-54-7
• 化学式: C₁₂H₂₄N₂O₄
• 分子量: 260.334
• InChiKey: HBCLYVIARHJTTL-VIFPVBQESA-N

物化性质

• 沸点：
  400.3±40.0 °C(Predicted)
• 密度：
  1.079±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  78.9
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 安全说明：
  S22,S26,S36/37/39

反应信息

• 作为反应物：
  描述：

  (S)-2-[(叔丁氧羰基)氨基]-5-(二甲基氨基)戊酸 在 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.0h， 生成 [(S)-4-amino-5-(4-{1-[2,4-dichloro-3-(2,4-dimethyl-quinolin-8-yloxymethyl)-benzenesulfonylamino]-cyclopentanecarbonyl}-piperazin-1-yl)-5-oxo-pentyl]-trimethyl-ammonium
  参考文献：
  名称：

  Design and Synthesis of Novel Sulfonamide-Containing Bradykinin hB₂ Receptor Antagonists. 2. Synthesis and Structure−Activity Relationships of α,α-Cycloalkylglycine Sulfonamides

  摘要：

  Recently we reported on the design and synthesis of a novel class of selective nonpeptide bradykinin (BK) B-2 receptor antagonists (J. Med. Chem. 2006, 3602-3613). This work led to the discovery of MEN 15442, an antagonist with subnanomolar affinity for the human B2 receptor (hB2R), which also displayed significant and prolonged activity in vivo (for up to 210 min) against BK-induced bronchoconstriction in the guinea-pig at a dose of 300 nmol/kg (it), while demonstrating only a slight effect on BK-induced hypotension. Here we describe the further optimization of this series of compounds aimed at maximizing the effect on bronchoconstriction and minimizing the effect on hypotension, with a view to developing topically delivered drugs for airway diseases. The work led to the discovery of MEN 16132, a compound which, after intratracheal or aerosol administration, inhibited, in a dose-dependent manner, BK-induced bronchoconstricton in the airways, while showing minimal systemic activity. This compound was selected as a preclinical candidate for the topical treatment of airway diseases involving kinin B2 receptor stimulation.

  DOI：

  10.1021/jm061143k
• 作为产物：
  描述：

  Boc-L-鸟氨酸 以60的产率得到(S)-2-[(叔丁氧羰基)氨基]-5-(二甲基氨基)戊酸
  参考文献：
  名称：

  J. Med. Chem. 2007, 50, 550-565

  摘要：

  DOI：

文献信息

• [EN] TGR5 AGONISTS<br/>[FR] AGONISTES DE TGR5
  申请人：EXELIXIS INC

  公开号：WO2011071565A1

  公开（公告）日：2011-06-16

  TGR5 agonists of structural formula VIII(Q), wherein X, R1, R2, and R5 are defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases.

  TGR5激动剂的结构式VIII(Q)，其中X、R1、R2和R5在规范中定义，其药用盐、组合物以及用于治疗疾病的化合物和组合物的使用。该发明还包括在制药品中使用这些化合物以及用于制造药物，特别是用于治疗疾病。
• Quinazoline derivatives useful in cancer treatment
  申请人：Mallams K. Alan

  公开号：US20070015774A1

  公开（公告）日：2007-01-18

  The present invention provides compounds of Formula I (wherein R 1 , R 2 , R 3 , L, and X are as defined herein). or a pharmaceutically acceptable salt, solvate or ester thereof. The present invention also provides compositions comprising these compounds that are useful for treating cellular proliferative diseases, disorders associated with activity of mutants of p53, or in causing apoptosis of cancer cells.

  本发明提供了式I的化合物（其中R1、R2、R3、L和X如本文所定义）。或其药用可接受的盐、溶剂或酯。本发明还提供了包含这些化合物的组合物，用于治疗细胞增殖性疾病、与p53突变体活性有关的疾病，或导致癌细胞凋亡。
• Effects of Chain Length and N-Methylation on a Cation–π Interaction in a β-Hairpin Peptide
  作者：Robert M. Hughes、Matthew L. Benshoff、Marcey L. Waters

  DOI：10.1002/chem.200601753

  日期：2007.7.6

  The effects of N-methylation and chain length on a cation-pi interaction have been investigated within the context of a beta-hairpin peptide. Significant enhancement of the interaction and structural stabilization of the hairpin have been observed upon Lys methylation. Thermodynamic analysis indicates an increased entropic driving force for folding upon methylation of Lys residues. Comparison of lysine

  在β-发夹肽的背景下，已经研究了N-甲基化和链长对阳离子-pi相互作用的影响。Lys甲基化后已观察到发夹相互作用和结构稳定的显着增强。热力学分析表明，当赖氨酸残基甲基化时，折叠时的熵驱动力增加。赖氨酸与类似物鸟氨酸（Orn）和二氨基丁酸（Dab）的比较表明，由于侧链-侧链相互作用和β-折叠倾向的结合，赖氨酸提供最强的阳离子-pi相互作用，还提供最稳定的β-发夹结构。这些研究对于识别组蛋白中的甲基化赖氨酸具有重要意义。
• TGR5 AGONISTS
  申请人：Bollu Venkataiah

  公开号：US20130303505A1

  公开（公告）日：2013-11-14

  TGR5 agonists of structural formula VIII(Q), wherein X, R 1 , R 2 , and R 5 are defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases.

  本发明涉及结构式VIII（Q）的TGR5激动剂，其中X、R1、R2和R5在规范中有定义，其药学上可接受的盐、组合物以及用于治疗疾病的化合物和组合物的用途。本发明还包括化合物的用途和用于制造药物，特别是用于治疗疾病。
• TGR5 agonists
  申请人：Bollu Venkataiah

  公开号：US08846739B2

  公开（公告）日：2014-09-30

  TGR5 agonists of structural formula VIII(Q), wherein X, R1, R2, and R5 are defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases.

  本发明涉及结构式VIII(Q)的TGR5激动剂，其中X、R1、R2和R5在说明书中有定义，其药学上可接受的盐、组成物以及用于治疗疾病的化合物和组合物的使用。本发明还包括将该化合物用于制造药物，特别是用于治疗疾病。